Author: Kevin Grogan

Switzerland’s Arpida says that its board of directors has approved a recently-announced set of cost-cutting measures as it gets to grips with a US regulatory panel’s rejection of the intravenous antibiotic iclaprim.

Abbott Laboratories is celebrating the news that US regulators have given the go-ahead to the firm’s cholesterol drug TriLipix.

GlaxoSmithKline and AstraZeneca have broadly welcomed the latest recommendations from a US Food and Drug Administration panel on the use of asthma medicines containing long-acting beta-agonists, though GSK is concerned about possible restrictions on the use of Serevent.

Lundbeck has announced plans to initiate three late-stage studies for the alcohol dependence drug nalmefene.

Bristol-Myers Squibb is giving Exelixis a $195 million upfront payment to get access to two of the latter firm’s promising oncology compounds.